AP
This biopharmaceutical company researches and develops psychedelic therapies specifically targeting stimulant addiction and related mental health disorders. By combining pharmaceutical interventions with personalized therapeutic approaches, the company enables patients to regain control over their recovery process.
Updated 2 months ago
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This biopharmaceutical company researches and develops psychedelic therapies specifically targeting stimulant addiction and related mental health disorders. By combining pharmaceutical interventions with personalized therapeutic approaches, the company enables patients to regain control over their recovery process.